OUR SCIENCE

Our genetically-engineered immune effector cell therapies, derived from induced pluripotent stem cells (iPSC) from healthy adults, are specifically designed to target hematologic and solid cancers and overcome barriers confronting autologous cell therapies.

OUR ALLOGENEIC, iPSC-BASED TECHNOLOGY

Leveraging our exclusive

cancer collaboration with FCDI

Century Reprogramming 1

REPROGRAMMING

Genome integration free reprogramming from healthy adult cells into renewable banks of iPSC

Century Differentiation 1

DIFFERENTIATION

Scalable, feeder-free differentiation into desired immune cell types

Century Expansion 1

MANUFACTURING

Most experience in generating uniform iPSC-derived products at a commercial scale

OUR PROCESS FROM iPSC TO PATIENT

1

iPSC

Century Step1

We start with induced pluripotent stem cells, a consistent and renewable source of cells derived from healthy adults

2

Design / Engineer

Century Step2

The cells are engineered to kill different types of tumors, persist, and overcome mechanisms of immune evasion

3

Expand / Bank

Century Step3

The cells are expanded and stored to create a renewable and reliable supply chain

4

Differentiate

Century Step4

Engineered iPSC are differentiated into T, NK, or other immune cells to generate products that specifically target different tumor types

5

Clinical Supply

Century Step5 06

Industry-leading capabilities and know-how to generate iPSC-derived immune cell therapies at a commercial scale

6

Cancer Patients

Century Step6 04

Uniform clinical supply ready and available for administration at any hospital

© Century Therapeutics 2019 | Legal